Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | CA9 | Q16790 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA7 | P43166 | 2/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16351851 | 1.00 | CA2 (0.66) | CA2CA9CA12CA1CA7 | |
| SCHEMBL235800 | 0.94 | CA2 (0.73) | CA2CA9CA12CA1CA7 | |
| SCHEMBL16351874 | 0.94 | CA1 (0.73) | CA2CA9CA12CA1CA7 | |
| SCHEMBL1965326 | 0.94 | CA1 (0.73) | CA2CA9CA12CA1CA7 | |
| Hydrochloric Acid SCHEMBL28242785 | 0.92 | CA2 (0.70) | CA2CA9CA12CA1CA7 | |
| SCHEMBL12544707 | 0.91 | CA12 (0.56) | CA2CA9CA12CA1CA7 | |
| SCHEMBL16351882 | 0.91 | CA12 (0.56) | CA2CA9CA12CA1CA7 | |
| SCHEMBL9581449 | 0.91 | CA12 (0.56) | CA2CA9CA12CA1CA7 | |
| SCHEMBL16351864 | 0.88 | CA12 (0.57) | CA2CA9CA12CA1CA7 | |
| SCHEMBL5556244 | 0.88 | CA12 (0.66) | CA2CA9CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567526-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9453103-B2 | Method for producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9238665-B2 | Method for producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150322199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322101-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5922898-A | Process for preparing biaryl compounds | CATALYTICA PHARMACEUTICALS, INC. (US) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322199-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | PAH, DDC, DDT | CA2 1064/4885CA9 330/4885CA12 889/4885 |
| US-20150322101-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | PAH, DDC, PHOSPHO1 | CA2 1031/4885CA9 387/4885CA12 780/4885 |
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CA2 2525/4885CA9 4131/4885CA12 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.